Apolipoprotein A-V Modulates Insulin Secretion in Pancreatic β-cells Through its Interaction with Midkine
暂无分享,去创建一个
H. Drobecq | L. Héliot | J. Fruchart | S. Helleboid | H. Dehondt | C. Rommens | E. Moitrot | M. Nowak | Audrey Helleboid-Chapman | J. Fruchart‐Najib
[1] C. Sergheraert,et al. Glucose regulates LXRα subcellular localization and function in rat pancreatic β-cells , 2006, Cell Research.
[2] J. Fruchart,et al. Is apolipoprotein A5 a novel regulator of triglyceride‐rich lipoproteins? , 2006, Annals of medicine.
[3] C. Sergheraert,et al. Glucose regulates LXRalpha subcellular localization and function in rat pancreatic beta-cells. , 2006, Cell Research.
[4] X. Prieur,et al. Thyroid Hormone Regulates the Hypotriglyceridemic Gene APOA5* , 2005, Journal of Biological Chemistry.
[5] L. Pennacchio,et al. Transcriptional Regulation of Apolipoprotein A5 Gene Expression by the Nuclear Receptor RORα , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[6] Y. Chiu,et al. Impact of Apolipoprotein A5 Polymorphisms on Insulin Sensitivity and β-cell Function , 2005, Pancreas.
[7] P. Strömstedt,et al. Identification of the human ApoAV gene as a novel RORα target gene , 2005 .
[8] L. Pennacchio,et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. , 2005, The Journal of biological chemistry.
[9] L. Pennacchio,et al. Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor , 2005, Molecular and Cellular Biology.
[10] A. Boodhoo,et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. , 2005, Clinical chemistry.
[11] A. Cantafora,et al. Inherited Apolipoprotein A-V Deficiency in Severe Hypertriglyceridemia , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[12] P. Strömstedt,et al. Identification of the human ApoAV gene as a novel RORalpha target gene. , 2005, Biochemical and biophysical research communications.
[13] L. Pennacchio,et al. The Liver X Receptor Ligand T0901317 Down-regulates APOA5 Gene Expression through Activation of SREBP-1c* , 2004, Journal of Biological Chemistry.
[14] L. Pennacchio,et al. Transcriptional Regulation of Apolipoprotein A5 Gene Expression by theNuclear Receptor ROR alpha , 2004 .
[15] K. V. van Dijk,et al. ApoAV Reduces Plasma Triglycerides by Inhibiting Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Production and Stimulating Lipoprotein Lipase-mediated VLDL-TG Hydrolysis* , 2004, Journal of Biological Chemistry.
[16] L. Pennacchio,et al. Analysis of Apolipoprotein A5, C3, and Plasma Triglyceride Concentrations in Genetically Engineered Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[17] V. Lánská,et al. The influence of APOAV polymorphisms (T‐1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction , 2004, Clinical genetics.
[18] Len A Pennacchio,et al. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. , 2004, Biochemical and biophysical research communications.
[19] X. Prieur,et al. The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-α and Contains a Novel Farnesoid X-activated Receptor Response Element* , 2003, Journal of Biological Chemistry.
[20] L. Pennacchio,et al. Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor α Activators* , 2003, The Journal of Biological Chemistry.
[21] B. Tomlinson,et al. APOA5‐1131T>C polymorphism is associated with triglyceride levels in Chinese men , 2003, Clinical genetics.
[22] P. Talmud,et al. Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. , 2003, Biochimica et biophysica acta.
[23] M. Olivier,et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. , 2002, Human molecular genetics.
[24] Jonathan C. Cohen,et al. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. , 2002, Human molecular genetics.
[25] M. Hirai,et al. Nuclear Targeting by the Growth Factor Midkine , 2002, Molecular and Cellular Biology.
[26] C. Powers,et al. Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types* , 2002, The Journal of Biological Chemistry.
[27] S. Tomura,et al. Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren , 2002, Human Genetics.
[28] J. Ribalta,et al. Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. , 2002, Clinical chemistry.
[29] R. Chamuleau,et al. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. , 2002, Biochemical and biophysical research communications.
[30] P. Wilson,et al. Diabetes mellitus and coronary heart disease. , 2001, Endocrinology and metabolism clinics of North America.
[31] P. Reitsma,et al. Apolipoprotein A-V , 2001, The Journal of Biological Chemistry.
[32] K. Zou,et al. Midkine binds to 37-kDa laminin binding protein precursor, leading to nuclear transport of the complex. , 2001, Experimental cell research.
[33] Jonathan C. Cohen,et al. An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.
[34] C. Locht,et al. Subtilisin‐like autotransporter serves as maturation protease in a bacterial secretion pathway , 2001, The EMBO journal.
[35] D. Jonas,et al. New molecular mediators in tumor angiogenesis , 2000, Journal of cellular and molecular medicine.
[36] K. Zou,et al. LDL receptor-related protein as a component of the midkine receptor. , 2000, Biochemical and biophysical research communications.
[37] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[38] M. Michikawa,et al. Midkine Inhibits Caspase‐Dependent Apoptosis via the Activation of Mitogen‐Activated Protein Kinase and Phosphatidylinositol 3‐Kinase in Cultured Neurons , 1999, Journal of neurochemistry.
[39] M. Noda,et al. A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. , 1999, The Journal of biological chemistry.
[40] T. Deuel,et al. Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. , 1999, Current opinion in hematology.
[41] T. Muramatsu,et al. Midkine, a retinoic acid-inducible heparin-binding cytokine, is a novel regulator of intracellular calcium in human neutrophils. , 1997, Biochemical and biophysical research communications.
[42] S. Kojima,et al. Dimerization of Midkine by Tissue Transglutaminase and Its Functional Implication* , 1997, The Journal of Biological Chemistry.
[43] H. Saito,et al. Expression of syndecan-1 and -3 during embryogenesis of the central nervous system in relation to binding with midkine. , 1997, Journal of biochemistry.
[44] S. Kojima,et al. Midkine Enhances Fibrinolytic Activity of Bovine Endothelial Cells (*) , 1995, The Journal of Biological Chemistry.
[45] I. Thesleff,et al. Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis. , 1995, Development.
[46] A. Nakagawara,et al. A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas. , 1993, Cancer research.
[47] H. Kondoh,et al. A retinoic acid responsive gene, MK, produces a secreted protein with heparin binding activity. , 1990, Biochemical and biophysical research communications.
[48] T. Muramatsu,et al. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. , 1988, Biochemical and biophysical research communications.
[49] J. Breslow. Apolipoprotein genetic variation and human disease. , 1988, Physiological reviews.
[50] J. Breslow,et al. Genetic mutations affecting human lipoprotein metabolism. , 1985, Advances in human genetics.